midazolam has been researched along with voriconazole in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, F; Chen, W; Lan, L; Li, B; Li, J; Liu, Y; Mao, F; Ni, S; Wei, H; Zhu, J | 1 |
| Laine, K; Leino, K; Neuvonen, PJ; Olkkola, KT; Saari, TI; Valtonen, M | 1 |
| Burhenne, J; Haefeli, WE; Katzenmaier, S; Markert, C; Mikus, G; Riedel, KD | 1 |
| Frechen, S; Fuhr, U; Junge, L; Neuvonen, PJ; Olkkola, KT; Rokitta, D; Saari, TI; Suleiman, AA | 1 |
| Burhenne, J; Carls, A; Haefeli, WE; Hohmann, N; Kocheise, F; Mikus, G; Weiss, J | 1 |
| Blank, A; Burhenne, J; Haefeli, WE; Hohmann, N; Kreuter, R; Mikus, G; Weiss, J | 1 |
| Dahlinger, D; Frechen, S; Fuhr, U; Goeser, T; Jaehde, U; Junge, L; Kinzig, M; Li, X; Sörgel, F; Starke, C; Stelzer, C; Taubert, M; Töx, U; von Georg, A | 1 |
| Chenel, M; Gautier-Veyret, E; Payen, L; Simon, F; Stanke-Labesque, F; Tod, M; Truffot, A | 1 |
| Burhenne, J; Gottwalt, K; Haefeli, WE; Hohmann, N; Huisinga, W; Kloft, C; Meid, AD; Michelet, R; Mikus, G; Nassar, YM | 1 |
1 review(s) available for midazolam and voriconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 trial(s) available for midazolam and voriconazole
| Article | Year |
|---|---|
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
Topics: Administration, Oral; Adult; Anesthetics, Intravenous; Antifungal Agents; Area Under Curve; Cross-Over Studies; Humans; Infusions, Intravenous; Male; Midazolam; Pyrimidines; Triazoles; Voriconazole | 2006 |
Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Female; Half-Life; Humans; Male; Midazolam; Middle Aged; Pyrimidines; Ritonavir; Time Factors; Triazoles; Voriconazole; Young Adult | 2011 |
A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.
Topics: Antifungal Agents; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Liver; Male; Midazolam; Models, Biological; Pyrimidines; Triazoles; Voriconazole | 2013 |
Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.
Topics: Administration, Intravenous; Administration, Oral; Adult; Area Under Curve; Biological Availability; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Voriconazole | 2016 |
A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
Topics: Adult; Anti-Anxiety Agents; Biotransformation; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Duodenum; Healthy Volunteers; Humans; Infusions, Intravenous; Infusions, Parenteral; Intestines; Liver; Male; Midazolam; Models, Biological; Pilot Projects; Voriconazole | 2020 |
Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion.
Topics: Administration, Oral; Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Humans; Midazolam; Pharmaceutical Preparations; Rifampin; Voriconazole | 2022 |
7 other study(ies) available for midazolam and voriconazole
| Article | Year |
|---|---|
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity.
Topics: Animals; Drug Design; Enzyme Inhibitors; ERG1 Potassium Channel; HEK293 Cells; Hep G2 Cells; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice; Oxidoreductases; Rats; Safety; Solubility; Structure-Activity Relationship; Water | 2018 |
Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics.
Topics: Adult; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Voriconazole; Young Adult | 2017 |
Modeling Approach to Predict the Impact of Inflammation on the Pharmacokinetics of CYP2C19 and CYP3A4 Substrates.
Topics: Antifungal Agents; Computer Simulation; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Humans; Inflammation; Midazolam; Models, Biological; Omeprazole; Voriconazole | 2021 |